Multisystem Processes & Disorders

Pelvic inflammatory disease: outpatient vs inpatient

Clinical Overview and When to Suspect PID

— Peak incidence age 15–25; ~1 million US cases/year, with substantial underdiagnosis in outpatient clinics.

— Risk factors: age <25, multiple partners, new partner in last 60 days, prior STI/PID, inconsistent condom use, douching, recent IUD insertion (only first 3 weeks).

— Most mild–moderate PID is managed outpatient with oral/IM regimens and 48–72 hour reassessment.

— Inpatient parenteral therapy is reserved for specific failure or severity criteria (covered in chunk 12).

Step 3 management: In an ambulatory clinic, a 22-year-old with new-partner pelvic pain and CMT gets a urine hCG, NAAT, HIV/syphilis testing, and same-visit empiric ceftriaxone + doxycycline + metronidazole — you do not send her home untreated awaiting NAAT results. This "treat-now, confirm-later" pattern is the single most testable concept of PID on Step 3.

Definition: Pelvic inflammatory disease (PID) is an ascending polymicrobial infection of the upper female genital tract — endometritis, salpingitis, tubo-ovarian abscess (TOA), pelvic peritonitis — typically arising from sexually transmitted pathogens (Chlamydia trachomatis, Neisseria gonorrhoeae) plus anaerobes, Mycoplasma genitalium, and vaginal flora.

Epidemiology:

When to suspect (CDC low threshold): sexually active woman with pelvic or lower abdominal pain and at least one of — cervical motion tenderness, uterine tenderness, or adnexal tenderness — and no other identifiable cause. Empirically treat; do not wait for labs.

Why the low threshold matters: Even subclinical PID causes tubal scarring. Delaying therapy increases infertility, ectopic pregnancy, and chronic pelvic pain risk substantially.

Outpatient vs inpatient framing (the Step 3 axis):

Differential trap: Always rule out pregnancy first — ectopic and septic abortion mimic PID and change management entirely.

Presentation Patterns and Key History

— Lower abdominal/pelvic pain — usually bilateral, dull, <2 weeks duration; worse with intercourse or movement.

— Abnormal vaginal discharge (mucopurulent), intermenstrual or postcoital bleeding.

— Dyspareunia, dysuria, low-grade fever, nausea.

— LMP and contraception (rule out pregnancy; IUD status).

— Sexual history: number of partners, new partner <60 days, condom use, partner symptoms, sexual orientation.

— Prior STIs, prior PID episodes (each recurrence multiplies infertility risk).

— HIV status, immunosuppression.

— Recent gynecologic instrumentation (D&C, hysteroscopy, IUD placement within 3 weeks).

— Allergies — especially cephalosporin/penicillin (changes regimen).

Key distinction: Cervicitis = lower tract only (mucopurulent discharge, no CMT, no upper-tract pain) → treat with single-dose ceftriaxone + doxycycline, no metronidazole needed and no PID workup. PID requires upper-tract tenderness on exam.

Classic symptom cluster:

Atypical/subclinical PID: Up to 60% of cases present with vague symptoms or are completely asymptomatic — discovered later as tubal factor infertility. Board pearl: A woman with infertility workup showing bilateral tubal occlusion on HSG and C. trachomatis IgG positivity had prior silent PID.

Right upper quadrant pain → Fitz-Hugh-Curtis syndrome (perihepatitis): seen in ~10%; pleuritic RUQ pain, "violin-string" adhesions between liver capsule and parietal peritoneum. Often mistaken for cholecystitis.

Severe presentation clues (think TOA or peritonitis): rigors, high fever >38.5°C, vomiting precluding oral intake, peritoneal signs, palpable adnexal mass.

History questions that change management:

Red-flag historical features: pregnancy, syncope, inability to tolerate PO, worsening despite 72h of outpatient therapy.

Physical Exam Findings and Hemodynamic Assessment

— Bilateral lower quadrant tenderness; rebound/guarding suggests peritonitis.

— RUQ tenderness without Murphy sign → Fitz-Hugh-Curtis.

— Palpable adnexal mass → suspect TOA.

— Speculum: mucopurulent cervical discharge, friable cervix that bleeds with swab contact ("cervical friability"). Collect NAAT here.

— Bimanual: at least one of the three minimum criteria must be present —

· Cervical motion tenderness ("chandelier sign")

· Uterine tenderness

· Adnexal tenderness

— Fullness or mass on adnexal palpation → image for TOA.

— Oral temp >38.3°C

— Mucopurulent cervical/vaginal discharge

— Abundant WBCs on saline wet mount of vaginal fluid (absence makes PID unlikely — good rule-out)

— Elevated ESR/CRP

— Documented cervical N. gonorrhoeae or C. trachomatis

CCS pearl: On CCS, order vital signs, pelvic exam, urine pregnancy test, NAAT for GC/CT, wet mount, CBC, and transvaginal ultrasound in the same initial click cluster. If you see "afebrile, tolerating PO, no peritoneal signs, no adnexal mass" — that patient goes home on outpatient therapy. If you see fever, vomiting, or mass — switch to admit, IV ceftriaxone/doxycycline/metronidazole, and gyn consult.

Vital signs first: Fever >38.3°C, tachycardia, or hypotension push toward inpatient care. Most outpatient-eligible PID patients are afebrile or low-grade febrile and hemodynamically normal.

Abdominal exam:

Pelvic exam — the diagnostic core:

CDC additional supportive criteria (increase specificity, not required):

Hemodynamic triage: Any SIRS criteria, orthostasis, or signs of sepsis → IV access, fluids, labs, admit.

Diagnostic Workup — Initial Labs and Imaging

— Urine β-hCG — rule out pregnancy first. Positive hCG with pelvic pain → ectopic until proven otherwise, and changes antibiotic choice (no doxycycline in pregnancy).

— Saline wet mount / vaginal pH — abundant PMNs supports PID; clue cells suggest BV co-infection; trichomonads → metronidazole.

— Cervical NAAT for N. gonorrhoeae and C. trachomatis (sensitivity >95%). Add M. genitalium NAAT if persistent symptoms or recurrence.

— HIV (4th-gen Ag/Ab) — PID is a high-yield opportunity for HIV screening.

— Syphilis (RPR or treponemal).

— Hepatitis B and C serologies if not up to date.

— Trichomonas NAAT (often bundled).

— WBC may be normal in mild PID — a normal CBC does not exclude PID.

— UA helps exclude pyelonephritis/UTI; sterile pyuria can occur with cervicitis/PID.

— Lactate if SIRS present.

— First-line imaging when PID is moderate–severe, mass palpated, or diagnosis uncertain.

— Findings: thickened (>5 mm) fluid-filled tubes ("cogwheel" sign), incomplete septa, tubo-ovarian complex/abscess, free pelvic fluid.

— Negative TVUS does not exclude PID (early/mild disease).

Board pearl: The single most important order in any suspected PID stem is the urine pregnancy test. Miss this and you miss ectopic pregnancy or shift to a teratogenic regimen. On Step 3, order it before any antibiotic. NAATs can be sent but should never delay empiric treatment.

Mandatory bedside tests:

Screening labs to obtain at same visit (CDC):

CBC, CMP, CRP/ESR, urinalysis:

Imaging — transvaginal ultrasound (TVUS):

CT abdomen/pelvis: reserved for unclear diagnosis, suspected appendicitis, or evaluating extent of abscess/peritonitis.

Diagnostic Workup — Advanced or Confirmatory Studies

— TVUS suggests TOA or complex fluid → confirm size, laterality, multilocularity.

— Concern for alternative diagnoses (appendicitis, diverticulitis, ovarian torsion, ruptured cyst) → CT with IV contrast.

— MRI pelvis when ultrasound equivocal in pregnancy or when radiation avoidance matters; highest sensitivity for TOA but rarely needed acutely.

— Histopathologic endometritis (plasma cells in endometrial stroma) is the most specific confirmatory test but rarely performed acutely — used in atypical cases, research, or when surgery occurs for another reason.

— Direct visualization of erythematous, edematous tubes with purulent exudate.

— Used when diagnosis is uncertain after failure of empiric therapy, when ruling out surgical abdomen, or for drainage of TOA refractory to antibiotics.

— Not routine — most PID is treated empirically without laparoscopy.

— Blood cultures if febrile/septic or admitted.

— Aspiration culture of TOA at drainage (image-guided) — directs anaerobic coverage.

— Consider M. genitalium testing in treatment failures; resistance to macrolides is now >50%, and moxifloxacin is the preferred salvage.

— TVUS to localize gestation; β-hCG quantitative + serial values.

— Septic abortion vs ectopic must be distinguished before any treatment plan.

Key distinction: PID vs TOA on imaging — uncomplicated PID shows hyperemic tubes and pelvic free fluid; TOA shows a discrete walled-off complex collection. TOA mandates inpatient IV antibiotics ± drainage, never outpatient oral therapy alone. Size >7 cm or failure to shrink at 48–72h tips toward image-guided drainage or surgery.

When to escalate imaging:

Endometrial biopsy:

Laparoscopy — gold standard:

Microbiology beyond NAAT:

Pregnancy testing if menstruating with positive hCG:

Risk Stratification — Outpatient vs Inpatient Decision

— Pregnancy

— Severe illness: high fever, nausea/vomiting, inability to tolerate oral regimen

— Tubo-ovarian abscess

— Surgical emergencies cannot be excluded (appendicitis, ectopic)

— Failure of outpatient therapy (no improvement at 72 hours)

— Inability to follow or tolerate an outpatient oral regimen (adherence, social factors)

— HIV-positive women with mild–moderate PID — recent data show comparable outcomes outpatient; admit only if severe.

— Adolescents — outpatient is acceptable if adherence is assured (older teaching to admit all teens has been abandoned).

— Women with IUDs — keep IUD in place initially; treat as standard PID; reassess at 48–72h, remove only if no improvement.

— Hemodynamically stable, afebrile or low-grade fever, tolerating PO, no TOA on imaging, reliable follow-up.

— Peritonitis, sepsis, TOA, pregnancy, vomiting, or diagnostic uncertainty.

— Same-visit empiric therapy, partner notification counseling, follow-up at 48–72 hours to confirm clinical improvement (defervescence, reduced tenderness).

— STI re-test at 3 months post-treatment (high reinfection rate, not test-of-cure).

Step 3 management: A 19-year-old afebrile, ambulatory, tolerating fluids, CMT and bilateral adnexal tenderness, no mass on TVUS → outpatient IM ceftriaxone 500 mg + doxycycline 100 mg PO BID × 14d + metronidazole 500 mg PO BID × 14d, with a return visit in 72 hours. Document the reassessment plan in the chart — this is both quality-of-care and medicolegal protection.

CDC criteria for inpatient (parenteral) therapy — any one triggers admission:

Patients NOT requiring admission by default:

Mild–moderate PID (outpatient candidate profile):

Severe PID (inpatient):

Disposition planning — outpatient pathway:

Pharmacotherapy — First-Line Regimens

— Ceftriaxone 500 mg IM × 1 (1 g if weight ≥150 kg)

— PLUS doxycycline 100 mg PO BID × 14 days

— PLUS metronidazole 500 mg PO BID × 14 days (now recommended for all PID — anaerobic coverage, BV-associated organisms, M. genitalium).

— Ceftriaxone 1 g IV q24h + doxycycline 100 mg IV/PO q12h + metronidazole 500 mg IV/PO q12h.

— Transition to PO doxycycline + metronidazole once clinically improved for 24–48h; complete 14 total days of therapy.

— Alternatives: cefotetan or cefoxitin + doxycycline (older regimens, still acceptable).

— Severe penicillin/cephalosporin allergy → consider clindamycin + gentamicin parenteral, or consult ID. Avoid fluoroquinolones empirically due to GC resistance unless local susceptibilities support and M. genitalium confirmed.

— NSAIDs for pain.

— Antiemetics if needed.

— Sexual abstinence until both partners complete therapy and are asymptomatic.

Board pearl: If the stem mentions BV, IUD, or any anaerobic source, metronidazole is required — but per current CDC, all PID regimens now include metronidazole regardless. A common distractor is the older 2-drug regimen; pick the 3-drug answer.

Outpatient regimen (CDC 2021, current):

Inpatient parenteral regimen (preferred):

Cephalosporin allergy:

Adjuncts:

Why metronidazole is now standard: Trials show better resolution of endometritis and improved coverage of anaerobes and M. genitalium–associated dysbiosis. Older "ceftriaxone + doxycycline only" regimens are out of date.

Use oral doxycycline whenever possible — IV doxycycline offers no clinical advantage and is more painful and expensive.

Procedures and Invasive Management — TOA and Surgery

— Always requires inpatient IV antibiotics first: ceftriaxone + doxycycline + metronidazole (or ampicillin-sulbactam + doxycycline).

— ~70% of TOAs <7 cm resolve with antibiotics alone.

— Continue IV until afebrile and improved ≥24–48h, then transition to oral doxycycline + metronidazole for total 14 days, with repeat imaging at 4–6 weeks to confirm resolution.

— Abscess ≥7 cm, persistent fever/tenderness or worsening on antibiotics >48–72h, hemodynamic instability, suspected rupture.

— Image-guided percutaneous or transvaginal drainage is preferred over surgery — minimally invasive, preserves fertility.

— Ruptured TOA (peritonitis, septic shock) — surgical emergency, broad-spectrum antibiotics, IR or OR.

— Failure of percutaneous drainage and continued sepsis.

— Diagnostic uncertainty with surgical abdomen.

— Do not remove the IUD reflexively. Leave in place during initial treatment and reassess at 48–72h.

— Remove only if no clinical improvement; modern guidelines de-emphasize early removal.

CCS pearl: For a hemodynamically unstable woman with ruptured TOA, the correct CCS sequence is IV access × 2 → fluids → cultures → IV antibiotics → emergent gyn/surgery consult → OR. Imaging confirmation should not delay resuscitation or operative consultation.

Tubo-ovarian abscess (TOA):

Drainage indications:

Surgical indications (laparoscopy/laparotomy):

IUD management:

Pregnancy with PID: rare but possible in first trimester pre-decidualization; admit, IV therapy, avoid doxycycline — use azithromycin + ceftriaxone + metronidazole; consult OB.

Septic shock pathway (CCS): ABCs → 30 mL/kg crystalloid → broad antibiotics within 1h (piperacillin-tazobactam or ceftriaxone+metronidazole+doxy) → ICU, vasopressors PRN, urgent gyn consult.

Special Populations — Elderly and Renal/Hepatic Impairment

— Always investigate for underlying gynecologic malignancy (endometrial, ovarian, tubal, cervical) or pyometra from cervical stenosis.

— TOA in postmenopausal women is malignancy until proven otherwise — requires CT, endometrial sampling, gyn-onc evaluation.

— Risk factors: recent instrumentation, diabetes, IUD retained from earlier in life.

— Same antibiotic backbone (ceftriaxone + doxycycline + metronidazole) but threshold to admit is lower due to atypical presentations, comorbidities, and higher rates of complications.

— Pelvic imaging mandatory; consider endometrial biopsy after acute infection resolves.

— Ceftriaxone — no renal dose adjustment, safe in CKD.

— Doxycycline — no renal dose adjustment, preferred tetracycline in renal disease.

— Metronidazole — minimal renal adjustment; in severe (CrCl <10 or HD) extend interval or reduce dose; pull off dialysis if possible.

— Aminoglycosides (if used in penicillin allergy) — adjust to creatinine clearance, monitor levels, avoid in elderly when alternatives exist.

— Doxycycline — generally safe; monitor LFTs in cholestasis.

— Metronidazole — reduce dose by ~50% in severe hepatic dysfunction (Child-Pugh C); accumulates with prolonged use.

— Avoid concurrent alcohol → disulfiram-like reaction with metronidazole; counsel for 72h after last dose.

— Doxycycline + warfarin → increased INR; check INR within several days.

— Metronidazole + warfarin → significant INR elevation; monitor closely or bridge.

— Doxycycline absorption reduced by antacids, iron, calcium — separate by 2 hours.

Key distinction: A 65-year-old with "PID" on imaging is not PID until cancer is excluded. Always re-image and biopsy after resolution. Treating empirically without follow-up is a frequent board trap.

Postmenopausal PID — uncommon but high-stakes:

Treatment in older adults:

Renal impairment:

Hepatic impairment:

Polypharmacy considerations:

Special Populations — Pregnancy, Adolescents, HIV, and IUD Users

— True PID after first trimester is rare (decidua seals the uterus).

— When suspected, admit all pregnant patients for IV therapy.

— Avoid doxycycline (teratogenic, tooth discoloration) — substitute with azithromycin + ceftriaxone + metronidazole (metronidazole is acceptable in all trimesters per CDC).

— Concurrent ectopic must be rigorously excluded.

— Manage with same regimens as adults, dosed by weight.

— Outpatient acceptable if reliable follow-up; the old "admit-all-teens" doctrine is obsolete.

— Confidentiality and consent — most US states allow minors to consent to STI care without parental notification; know your state's rules.

— Routine HIV, syphilis, pregnancy testing at the visit.

— Higher rates of TOA and atypical organisms but respond to standard regimens.

— Outpatient treatment acceptable if mild–moderate; lower threshold to admit if CD4 <200 or evidence of complications.

— Confirm HAART adherence and screen for other OIs.

— Insertion-related PID risk is highest in the first 3 weeks post-placement.

— Do not remove reflexively — leave in place, treat with standard regimen, reassess at 48–72h, remove only if no clinical improvement.

— Counsel on long-acting contraception continuation; pregnancy still preventable during treatment.

— Polymicrobial; treat with clindamycin + gentamicin (classic regimen) or ampicillin-sulbactam.

— Distinct from sexually acquired PID — different organisms (Group B Strep, anaerobes, enterics).

Step 3 management: A 16-year-old presents with CMT and discharge, asks you not to tell her parents. In most states, you can provide confidential STI evaluation and treatment, document the discussion, and proceed with empiric outpatient therapy. Forced disclosure can drive teens away from care entirely.

Pregnancy:

Adolescents (age <18):

HIV-positive women:

IUD in situ:

Postpartum/post-instrumentation endometritis:

Complications and Adverse Outcomes

— Tubo-ovarian abscess — develops in ~15–30% of admitted patients; risk of rupture → peritonitis, septic shock, mortality.

— Fitz-Hugh-Curtis syndrome — perihepatitis with violin-string adhesions; treated with same PID regimen, no separate antibiotic needed.

— Sepsis/septic shock — from ruptured TOA or bacteremia.

— Reactive arthritis (especially with chlamydia) — conjunctivitis, urethritis, asymmetric oligoarthritis.

— Infertility — risk per episode: ~12% after 1st, ~25% after 2nd, ~50% after 3rd. Tubal factor infertility is the dominant mechanism.

— Ectopic pregnancy — 6–10× increased risk due to tubal scarring; counsel any post-PID pregnancy to present early for dating ultrasound.

— Chronic pelvic pain — up to 30–40% of women after PID develop persistent pelvic pain; multifactorial (adhesions, neuropathic).

— Recurrent PID — high rate; ~20–25% within 2 years.

— Delay in treatment >72h from symptom onset.

— Severe disease, TOA at presentation.

— Repeat episodes.

— Smoking, douching, ongoing untreated partners.

Board pearl: Every recurrence approximately doubles infertility risk. This is the single most important counseling point at discharge — emphasize partner treatment, condom use, and rescreening at 3 months to prevent reinfection. A stem describing "second episode of PID at age 23, now trying to conceive" should prompt early reproductive endocrinology referral and HSG for tubal patency assessment.

Acute complications:

Chronic complications (the long tail that defines PID's morbidity):

Predictors of worse outcome:

Mortality: rare in modern era but real with ruptured TOA — historically up to 5–10%; current <1% with timely surgery and antibiotics.

When to Escalate — Inpatient Triage and Consultation

— Pregnancy with confirmed or suspected PID.

— Inability to tolerate PO (nausea, vomiting).

— Severe illness: T >38.5°C, peritoneal signs, hypotension, tachycardia.

— Tubo-ovarian abscess on imaging.

— Cannot exclude surgical emergency (appendicitis, ovarian torsion, ectopic).

— Failed outpatient therapy: no improvement at 72 hours despite adherence.

— Adherence/social barriers preventing reliable outpatient care.

— Gynecology — for any TOA, surgical candidate, or pregnant patient. Early consult prevents delay.

— Interventional radiology — for image-guided abscess drainage.

— Infectious disease — atypical organisms, severe allergy, treatment failure, immunocompromised.

— Social work — partner notification logistics, contraception counseling, intimate partner violence screening.

— Septic shock (vasopressor requirement, lactate >4, qSOFA ≥2 with infection).

— Ruptured TOA with peritonitis.

— Multiorgan dysfunction.

— Reassess diagnosis — image again, exclude TOA, appendicitis, endometrioma.

— Reassess adherence and consider observed therapy.

— Broaden antibiotics; consider M. genitalium-directed moxifloxacin if NAAT positive.

— Surgical/IR consult for drainage if abscess persists.

CCS pearl: On a CCS case of severe PID, your gyn consult should be ordered in the first screen along with antibiotics and imaging. Delaying consultation until imaging returns is a common scoring deduction. Document handoffs with vitals and exam findings explicitly.

Immediate admission triggers (re-emphasized as decision logic):

Consultations:

ICU criteria:

Failure-to-improve workflow at 72 hours:

Outpatient → inpatient conversion: any patient initially treated outpatient who returns with worsening symptoms, fever, or signs of TOA → admit, IV antibiotics, imaging.

Key Differentials — Gynecologic Causes

— Positive β-hCG with no IUP on TVUS; unilateral pain, vaginal bleeding, possible adnexal mass.

— Highest-priority rule-out — missing it is potentially fatal.

— Sudden severe unilateral pain, nausea/vomiting, palpable adnexal mass.

— TVUS with Doppler showing absent/diminished ovarian flow.

— Surgical emergency — detorsion within 6–8h to preserve viability.

— Mid-cycle, sudden sharp pain, free fluid on US, often resolves with observation/NSAIDs.

— Chronic cyclic pelvic pain, dyspareunia, dysmenorrhea, infertility.

— Tender uterosacral nodularity; lacks acute fever and discharge.

— Discrete walled-off collection on imaging; admit + IV antibiotics ± drainage.

— Recent pregnancy/miscarriage with fever, foul discharge, uterine tenderness.

— Requires evacuation + broad-spectrum antibiotics.

— Mucopurulent discharge without CMT or upper-tract tenderness.

— Treated with ceftriaxone + doxycycline; no metronidazole, no 14-day course required.

— PID is acute (<2 weeks), febrile, with discharge and elevated inflammatory markers; endometriosis is chronic, cyclic, afebrile.

Key distinction: Unilateral severe pain with mass = torsion or ectopic until proven otherwise. Bilateral lower-quadrant pain with CMT and discharge = PID. Bilaterality is one of the most reliable clinical pointers toward ascending infection rather than a focal adnexal pathology.

Ectopic pregnancy:

Ovarian torsion:

Ruptured ovarian cyst (hemorrhagic corpus luteum):

Endometriosis:

Tubo-ovarian abscess (PID complication, separate management):

Septic abortion:

Cervicitis (lower tract only):

Endometriosis vs PID acutely:

Key Differentials — Non-Gynecologic Causes

— Migratory periumbilical → RLQ pain, anorexia, McBurney point tenderness, low-grade fever.

— Hard to distinguish from right-sided PID; CT abdomen/pelvis with contrast is definitive.

— Pregnancy with RLQ pain → MRI or US first to limit radiation.

— Dysuria, frequency, flank pain, costovertebral angle tenderness, fever; UA with pyuria, nitrites, leukocyte esterase.

— Sterile pyuria can occur with cervicitis — don't anchor on UA alone.

— Colicky flank pain radiating to groin, hematuria; CT without contrast diagnostic.

— Diverticulitis: left lower quadrant pain, older patient, change in bowel habits, CT shows pericolonic inflammation.

— IBD: chronic diarrhea, weight loss, bloody stools.

— Chronic, fluctuating, relieved by defecation; no fever, normal exam.

— Younger patients, viral prodrome, RLQ pain, enlarged lymph nodes on imaging — self-limited.

— Reproducible with palpation of specific muscles or pelvic floor; chronic; no fever or discharge.

— Always screen for intimate partner violence and sexual trauma when pain is chronic, recurrent, or out of proportion.

Board pearl: A young woman with RLQ pain, fever, and CMT — order both β-hCG and CT (or US) before committing to a diagnosis. Appendicitis and right-sided PID coexist often enough that a single empiric label can miss the surgical pathology. Always document a deliberate differential in the chart.

Acute appendicitis:

Urinary tract infection / pyelonephritis:

Nephrolithiasis:

Inflammatory bowel disease / diverticulitis:

Irritable bowel syndrome:

Mesenteric adenitis:

Functional / musculoskeletal pelvic pain:

Psychosomatic and abuse-related pelvic pain:

Secondary Prevention, Discharge Plan, and Long-Term Care

— Ceftriaxone 500 mg IM was given in clinic.

— Doxycycline 100 mg PO BID × 14 days.

— Metronidazole 500 mg PO BID × 14 days; counsel no alcohol during and 72h after.

— NSAIDs PRN.

— Sexual abstinence until completion of therapy AND partner(s) treated and asymptomatic.

— Partner notification and treatment — all partners within last 60 days must be evaluated/treated. Expedited partner therapy (EPT) legal in most US states for chlamydia (and gonorrhea in many) — provide a partner Rx or pharmacy referral.

— Condom use going forward; offer LARC counseling.

— Warning signs to return: worsening pain, fever, vomiting, syncope.

— Repeat NAAT for GC/CT at 3 months after treatment — high reinfection rate, not assessing cure.

— Test-of-cure only required in pregnancy or persistent symptoms.

— Discuss HIV PrEP (tenofovir/emtricitabine) for ongoing risk.

— Update HPV vaccination if age-eligible (through 26, individualized through 45).

— Hepatitis B vaccination if not immune.

— Continue IUD if it's working; PID is not a contraindication to LARC long-term.

— Reinforce dual protection (condoms + hormonal/LARC).

— After first episode, advise early pregnancy ultrasound to localize gestation given ectopic risk.

— After recurrent PID, consider referral to reproductive endocrinology if conception delayed >6 months.

Step 3 management: EPT is a high-yield Step 3 point — when the partner is unwilling/unable to attend, give the patient a Rx (azithromycin 1 g or doxycycline 100 mg BID × 7d) to give to her partner, documenting the discussion. This is endorsed by CDC and legal in most states.

Same-day discharge medications (outpatient PID):

Patient counseling at discharge:

Rescreening (not test-of-cure):

HIV/STI prevention bundle:

Contraception:

Fertility counseling:

Follow-Up, Monitoring, and Rehab/Counseling

— In-person preferred; telephone acceptable if reliable.

— Assess: defervescence, reduction in pelvic tenderness, ability to take PO, adherence.

— No improvement → admit for IV therapy and repeat imaging.

— Confirm resolution of symptoms.

— Reinforce abstinence until partners treated, contraception, prevention.

— Document partner notification outcome.

— NAAT for chlamydia and gonorrhoea (not test-of-cure — detects reinfection).

— Repeat HIV and syphilis if ongoing risk.

— Counsel about chronic pelvic pain risk; offer referral to pelvic pain clinic if persistent.

— Annual STI screening for women <25 or with ongoing risk per USPSTF.

— Track contraception efficacy and IUD position.

— Document each PID episode; advise patients planning future pregnancy to seek early evaluation if conception delayed beyond 6 months (instead of standard 12 months at age <35).

— Motivational interviewing on condom use, partner reduction.

— Substance use screening — high overlap with STI risk.

— Mental health screening — depression, IPV common after PID.

— Repeat imaging at 4–6 weeks to confirm resolution.

— If residual mass persists or grows, image again and consider gyn-onc evaluation, especially in postmenopausal women.

CCS pearl: On CCS, after starting outpatient PID therapy, advance the clock to 72 hours and schedule a clinic reassessment. Forgetting the follow-up appointment can cost points. Also schedule the 3-month STI rescreen before ending the case.

48–72 hour reassessment (mandatory for all outpatient PID):

End-of-treatment visit (day 14–28):

3-month rescreening:

Long-term monitoring:

Fertility surveillance:

Behavioral counseling:

TOA follow-up specifically:

Ethical, Legal, and Patient Safety Considerations

— Most US states permit minors to consent to STI evaluation and treatment without parental notification.

— Know that billing/EOB statements can inadvertently disclose — counsel patients on this risk; offer cash payment or confidential billing where available.

— Document the rationale for confidential care in the chart.

— Gonorrhea, chlamydia, syphilis, HIV are reportable diseases in all US states — clinician/lab responsibility.

— Sexual abuse of a minor → mandatory reporter obligation; report regardless of patient wishes.

— Intimate partner violence — screen routinely; reporting laws vary by state (some mandate reporting of injuries from violence).

— Legal in most states; check local statutes.

— Document discussion, informed consent for the partner-by-proxy prescription.

— Drainage of TOA or surgery requires consent including infertility risk discussion.

— Pregnancy decisions in setting of septic abortion require non-coercive counseling and respect of patient autonomy.

— Discharge from ED on outpatient PID regimen — explicit follow-up appointment within 72h, written instructions, return precautions, contact number.

— Verify pharmacy fill of the metronidazole and doxycycline; many "treatment failures" are actually unfilled prescriptions.

— Anchor bias is the major safety issue — labeling all pelvic pain in young women "PID" can miss ectopic, torsion, or appendicitis.

— Always re-document pregnancy test result and consideration of surgical differentials.

— Counsel without judgment; PID disproportionately affects under-resourced populations and racialized communities; structural barriers drive recurrence.

Step 3 management: The medicolegal high-yield item is failure to document the 72-hour reassessment plan and pregnancy test result. Both should appear in every PID note.

Adolescent confidentiality:

Mandatory reporting:

Expedited Partner Therapy (EPT):

Informed consent for procedures:

Transition-of-care safety (Step 3 staple):

Diagnostic safety:

Stigma and equity:

High-Yield Associations and Rapid-Fire Facts

Board pearl: When a stem says "young woman, pelvic pain, mucopurulent cervicitis, RUQ pain too" — answer is Fitz-Hugh-Curtis; treatment is the same PID regimen, no extra antibiotic needed.

Fitz-Hugh-Curtis syndrome = perihepatitis from ascending GC/CT → RUQ pain + violin-string adhesions on laparoscopy. Treat with standard PID regimen.

Reactive arthritis (Reiter) = "can't see, can't pee, can't climb a tree" — conjunctivitis, urethritis, asymmetric oligoarthritis after chlamydial infection; HLA-B27 associated.

Lymphogranuloma venereum = C. trachomatis serovars L1–L3 → painless genital ulcer, then inguinal buboes ("groove sign"). Treat with doxycycline × 21 days.

Disseminated gonococcal infection (DGI) = triad of dermatitis (pustular skin lesions), tenosynovitis, migratory polyarthritis OR purulent septic monoarthritis. Treat with IV ceftriaxone.

IUD and PID = elevated risk only in first 3 weeks post-insertion. After that, IUDs do not increase PID risk.

Mycoplasma genitalium — emerging cause of persistent PID; macrolide resistance >50%; treat with moxifloxacin if confirmed.

Trichomonas — frequently coexists; treat with metronidazole (already in PID regimen) but treat the partner explicitly.

Bacterial vaginosis — strongly associated with PID via dysbiosis; metronidazole covers both.

Pregnancy after PID — early dating ultrasound mandatory due to ectopic risk.

Postmenopausal "PID" — investigate for malignancy.

HIV co-infection — increases TOA risk; still treat with standard regimen.

Sexual abstinence for both partners until therapy complete AND asymptomatic.

Rescreen at 3 months, not test-of-cure.

Metronidazole + alcohol = disulfiram reaction (flushing, nausea, tachycardia).

Doxycycline contraindications: pregnancy, breastfeeding (relative), children <8.

Cervical motion tenderness ("chandelier sign") — pathognomonic exam finding for upper tract inflammation.

Board Question Stem Patterns

— 22-year-old with bilateral pelvic pain, new partner, mucopurulent discharge, CMT, afebrile, tolerating PO, negative β-hCG, no mass on US.

— Answer: Outpatient ceftriaxone IM + doxycycline + metronidazole × 14d, follow-up 72h.

— Fever 39°C, vomiting, 6-cm complex adnexal collection on TVUS.

— Answer: Admit, IV ceftriaxone + doxycycline + metronidazole, gyn consult, repeat imaging.

— Hypotension, peritonitis, free fluid.

— Answer: Fluids → broad antibiotics → emergent surgery; do not delay for imaging.

— Pelvic pain + pleuritic RUQ pain in sexually active young woman, normal LFTs/US.

— Answer: Standard PID regimen; no need for separate hepatic workup.

— Always β-hCG first; positive → rule out ectopic before labeling PID.

— Patient has Mirena, develops PID. Do not remove IUD initially; treat and reassess at 72h.

— 16-year-old asks you not to inform parents about STI evaluation.

— Answer: Provide confidential care per state law; counsel on EOB disclosure.

— Patient returns at day 4 unchanged; admit, image for TOA, broaden coverage, test for M. genitalium.

— Third episode at age 25, trying to conceive → counsel about tubal infertility, refer to REI, HSG.

— Workup for malignancy; do not treat as routine PID.

Step 3 management: The most common wrong answer is choosing ceftriaxone + doxycycline without metronidazole. Current CDC guidelines mandate metronidazole in all PID regimens — pick the three-drug answer every time unless the stem specifies a contraindication.

Stem pattern 1 — Classic outpatient PID:

Stem pattern 2 — TOA / inpatient PID:

Stem pattern 3 — Ruptured TOA:

Stem pattern 4 — Fitz-Hugh-Curtis:

Stem pattern 5 — Pregnancy + pelvic pain:

Stem pattern 6 — IUD and PID:

Stem pattern 7 — Adolescent confidentiality:

Stem pattern 8 — Treatment failure:

Stem pattern 9 — Recurrent PID and infertility:

Stem pattern 10 — Postmenopausal "PID":

One-Line Recap

Pelvic inflammatory disease is treated empirically with ceftriaxone 500 mg IM + doxycycline 100 mg PO BID + metronidazole 500 mg PO BID × 14 days at the first visit in any sexually active woman with pelvic pain plus cervical motion, uterine, or adnexal tenderness — outpatient for mild–moderate disease, inpatient IV therapy for pregnancy, severe illness, TOA, vomiting, surgical uncertainty, or failure at 72 hours.

Board pearl: Three-drug regimen, 14 days, 72-hour reassessment, 3-month rescreen — memorize these four numbers and most PID stems on Step 3 collapse into a clean answer.

Diagnostic anchor: Urine β-hCG + NAAT for GC/CT + wet mount + TVUS if moderate/severe; do not delay antibiotics waiting on NAAT — empirical treatment is the standard of care because tubal damage accrues with every hour of delay.

Disposition logic: Outpatient if hemodynamically stable, afebrile or low-grade, tolerating PO, no TOA, and reliable follow-up. Admit for pregnancy, TOA, severe systemic illness, inability to tolerate PO, diagnostic uncertainty, or 72-hour outpatient failure. TOA ≥7 cm or persistent → image-guided drainage; ruptured TOA → emergent surgery.

Long-term care: 48–72 hour reassessment, partner notification with expedited partner therapy where legal, NAAT rescreening at 3 months (not test-of-cure), counseling on infertility and ectopic pregnancy risk, condom and LARC promotion, and HIV PrEP discussion. Each PID recurrence doubles infertility risk.

High-yield traps: Don't remove IUDs reflexively, don't forget metronidazole (now standard), don't anchor on PID in postmenopausal women (rule out malignancy), don't omit pregnancy test, don't skip the 72-hour follow-up plan, and use azithromycin (not doxycycline) if pregnant.